Pulmonary Embolism Identification Solution From RapidAI Scores FDA Clearance

San Mateo, California-based stroke decision support company RapidAI has earned an FDA clearance for its Rapid PE Triage & Notification, a software meant to accelerate identification and strengthen treatment support for the deadly lung artery blockage known as pulmonary embolism (PE). RapidAI is well known for its clinical decision support solutions leveraging AI-enabled imaging software, many of which help doctors in addressing the needs of stroke patients. Now, with its advanced innovations for PE, which includes its compatible Rapid Workflow for PE tool, care teams have a means to get a better handle on patient care journeys.

“Building on our expertise in stroke, we’re confident this technology will help modernize PE care and meaningfully improve patient outcomes,” said RapidAI Chief Executive Officer Karim Karti. “Our goal is to build solutions that address the specific challenges associated with treating various conditions, as well as the communication and workflow issues faced by hospitals globally.”

Become a Subscriber

Please purchase a subscription to continue reading this article.

Subscribe Now

The software can automatically spot a suspected central pulmonary embolism located in the lung’s central arteries, then provide real-time notification to physicians. PE is often caused by deep vein thrombosis, and according to the Centers for Disease Control and Prevention(CDC), together they are responsible for around 100,000 deaths in the U.S. per year – with a particular skew toward the over-65 demographic. The CDC reports that approximately one quarter of these patients experience sudden death as the first “sign” of PE. Moreover, recurrence of PE within a decade occurs for one third of individuals. Treatment is usually given in the form of medications such as blood thinners, and in some cases surgical clot removal comes into play.